In the News
Q&A: Sepsis detection technology that can triage COVID-19 patients
Ian Bolland caught up with Dr. Rolland Carlson, CEO of Immunexpress, to talk about a molecular diagnostic, SeptiCyte RAPID, which is used to detect sepsis and offers the potential to triage severe COVID-19 patients in the emergency department. Expand Briefly, tell us more about Immunexpress – how did the idea...
Immunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch
Immunexpress and its partner Biocartis plan to introduce a new, rapid test for sepsis in Europe this quarter ahead of a potential US Food and Drug Administration 510(k) clearance for the assay later this year. The companies are positioning the test, called SeptiCyte Rapid, to triage COVID-19 patients who could...
Immunexpress – Near-Patient Diagnostic For Sepsis – SeptiCyte® RAPID
Dr. Rollie Carlson, CEO of Immunexpress discusses the development and commercialization plans for SeptiCyte® RAPID. SeptiCyte® RAPID is a test that quantifies the immune response to infection and will provide actionable results in about one hour to guide physicians when making patient management decisions.
Conquering Sepsis Clinical Trial Design
Designing and operating clinical trials for diagnosing sepsis can be a challenge, as the gold standard for sepsis detection offers a very low prediction rate due to the nature of how sepsis evolves in patients. FDA gold-standard septic blood cultures predict sepsis only 14% of the time, which makes it...
Biocartis Group partners with Immunexpress
For co-commercialisation agreement for SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla Biocartis Group recently announced the expansion of its partnership with Immunexpress with a co-commercialisation agreement for the SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla. The SeptiCyte RAPID...
Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test
Biocartis has expanded its current partnership with Seattle-based Immunexpress by launching a co-commercialization agreement for Immunexpress' SeptiCyte Rapid test on Biocartis' Idylla platform. As part of the expanded collaboration, Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the...
Q&A: BARDA Director Rick Bright Discusses New Programs, Focus on Diagnostics
Rick Bright joined the Biomedical Advanced Research and Development Authority in 2010 following a scientific career addressing influenza at the US Centers for Disease Control and Prevention and at PATH, plus a stint in industry at a vaccine development firm. Now a 12-year-old agency, BARDA was always intended to be...
Execs On The Move: Marketing And Sales Appointments At Quest, SomaLogic And Immunexpress
Quest Diagnostics and SomaLogic, a protein biomarker discovery and diagnostics company, will each bring on a new chief commercial officer; Immunexpress, a sepsis diagnostics firm, hired a VP for market development and commercial operations; and more.
Surviving sepsis: Beth’s story
https://www.youtube.com/watch?v=59ssju37pFY There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But...
Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress. Specific terms of the deal were not disclosed. Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....
Medical Device Daily – Other News to Note
Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation...
Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay. The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is...